Terms: = Breast cancer AND MUC16, CA125, CA-125 AND Diagnosis
190 results:
1. Integrated proteogenomic and metabolomic characterization of papillary thyroid cancer with different recurrence risks.
Qu N; Chen D; Ma B; Zhang L; Wang Q; Wang Y; Wang H; Ni Z; Wang W; Liao T; Xiang J; Wang Y; Jin S; Xue D; Wu W; Wang Y; Ji Q; He H; Piao HL; Shi R
Nat Commun; 2024 Apr; 15(1):3175. PubMed ID: 38609408
[TBL] [Abstract] [Full Text] [Related]
2. Machine learning-based models for the prediction of breast cancer recurrence risk.
Zuo D; Yang L; Jin Y; Qi H; Liu Y; Ren L
BMC Med Inform Decis Mak; 2023 Nov; 23(1):276. PubMed ID: 38031071
[TBL] [Abstract] [Full Text] [Related]
3. Development and validation of prediction model for early warning of ovarian metastasis risk of endometrial carcinoma.
Zhao Q; Li Y; Wang T
Medicine (Baltimore); 2023 Oct; 102(41):e35439. PubMed ID: 37832099
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of Serum Fructosamine as Diagnostic Marker of Postoperative Recurrence in the Patients with breast cancer.
Zhao Y; Xie X; Xie J; Zhang L; Li B; Liu J; Jiang H
Biomed Res Int; 2023; 2023():6435776. PubMed ID: 37475819
[TBL] [Abstract] [Full Text] [Related]
5. The mutational landscape of a US Midwestern breast cancer cohort reveals subtype-specific cancer drivers and prognostic markers.
Vellichirammal NN; Tan YD; Xiao P; Eudy J; Shats O; Kelly D; Desler M; Cowan K; Guda C
Hum Genomics; 2023 Jul; 17(1):64. PubMed ID: 37454130
[TBL] [Abstract] [Full Text] [Related]
6. Randomized trial of exercise on cancer-related blood biomarkers and survival in women with ovarian cancer.
Cartmel B; Li FY; Zhou Y; Gottlieb L; Lu L; Mszar R; Harrigan M; Ligibel JA; Gogoi R; Schwartz PE; Risch HA; Irwin ML
Cancer Med; 2023 Jul; 12(14):15492-15503. PubMed ID: 37269192
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA Dysregulation in Early breast cancer diagnosis: A Systematic Review and Meta-Analysis.
Garrido-Palacios A; Rojas Carvajal AM; Núñez-Negrillo AM; Cortés-Martín J; Sánchez-García JC; Aguilar-Cordero MJ
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175974
[TBL] [Abstract] [Full Text] [Related]
8. Could uterine conservation be an option in presumed early-stage epithelial ovarian cancer?
Benoit L; Pajot C; Koual M; Nguyen-Xuan HT; Bentivegna E; Bats AS; Azaïs H
Arch Gynecol Obstet; 2023 Sep; 308(3):953-960. PubMed ID: 37031304
[TBL] [Abstract] [Full Text] [Related]
9. Phase II Trials of Iniparib (BSI-201) in Combination with Gemcitabine and Carboplatin in Patients with Recurrent Ovarian cancer.
Penson RT; Ambrosio AJ; Whalen CA; Krasner CN; Konstantinopoulos PA; Bradley C; Matulonis UA; Birrer MJ
Oncologist; 2023 Mar; 28(3):252-257. PubMed ID: 36718018
[TBL] [Abstract] [Full Text] [Related]
10. Correlation of TBK1, AR, and other serum cancer-related biomarkers in breast cancer patients: An observational study.
Liu H; Li H; Zhang J; Meng Q; Ma L
Medicine (Baltimore); 2022 Aug; 101(33):e29996. PubMed ID: 35984205
[TBL] [Abstract] [Full Text] [Related]
11. Plasma Profile of Immune Determinants Predicts Pathological Complete Response in Locally Advanced breast cancer Patients: A Pilot Study.
Miceli R; Cao C; Maolanon NN; Jacobs R; Wu J; Orlandi R
Clin Breast Cancer; 2022 Oct; 22(7):705-714. PubMed ID: 35725806
[TBL] [Abstract] [Full Text] [Related]
12. Ovarian Masses in Patients With breast cancer.
Kang KA; Lee J; Kim HS; Park SY
J Comput Assist Tomogr; 2022 Sep-Oct 01; 46(5):716-721. PubMed ID: 35617667
[TBL] [Abstract] [Full Text] [Related]
13. Neuron-Specific Enolase and Hemoglobin as Risk Factors of Intraocular Metastasis in Patients with Renal Cell Carcinoma.
Li QY; Su T; Shi WQ; Fang JW; Zhang MY; Xu QH; Liang RB; Ge QM; Li B; Shao Y
Dis Markers; 2022; 2022():2883029. PubMed ID: 35502301
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic Value of Combined Lactate Dehydrogenase, C-Reactive Protein, cancer Antigen 153 and cancer Antigen 125 in Metastatic breast cancer.
Ma YY; Wang H; Zhao WD; Li YF; Wang JJ; Chen XY; Huang YQ; Wang WJ; Wang Y; Sun SC
Cancer Control; 2022; 29():10732748211053150. PubMed ID: 34989251
[TBL] [Abstract] [Full Text] [Related]
15. Combination of Neutrophil-to-Lymphocyte Ratio and Red Cell Distribution Width With Serum Tumor Markers for the Differential diagnosis of breast cancer and its Association With Pathological Features and Molecular Types.
Zou H; Liu SH; Yang R; Wu XJ; Cao YP; Huang HF
Clin Breast Cancer; 2022 Jun; 22(4):e526-e535. PubMed ID: 34963613
[TBL] [Abstract] [Full Text] [Related]
16. Detection of folate receptor-positive circulating tumor cells as a biomarker for diagnosis, prognostication, and therapeutic monitoring in breast cancer.
Wu Q; Zheng H; Gu J; Cheng Y; Qiao B; Wang J; Xiong L; Sun S; Wu Z; Bao A; Tong Y
J Clin Lab Anal; 2022 Jan; 36(1):e24180. PubMed ID: 34919735
[TBL] [Abstract] [Full Text] [Related]
17. Three-dimensional porous calcium alginate fluorescence bead-based immunoassay for highly sensitive early diagnosis of breast cancer.
Chia YY; Theverajah TM; Alias Y; Khor SM
Anal Bioanal Chem; 2022 Jan; 414(3):1359-1373. PubMed ID: 34839383
[TBL] [Abstract] [Full Text] [Related]
18. The challenging screen detection of ovarian cancer in BRCA mutation carriers adhering to a 6-month follow-up program: results from a 6-years surveillance.
Grandi G; Fiocchi F; Cortesi L; Toss A; Boselli F; Sammarini M; Sighinolfi G; Facchinetti F
Menopause; 2021 Nov; 29(1):63-72. PubMed ID: 34726192
[TBL] [Abstract] [Full Text] [Related]
19. Potential of combination of DCE-MRI and DWI with serum ca125 and CA199 in evaluating effectiveness of neoadjuvant chemotherapy in breast cancer.
Zhang J; Huang Y; Chen J; Wang X; Ma H
World J Surg Oncol; 2021 Sep; 19(1):284. PubMed ID: 34537053
[TBL] [Abstract] [Full Text] [Related]
20. Ultrasensitive, high-throughput and multiple cancer biomarkers simultaneous detection in serum based on graphene oxide quantum dots integrated microfluidic biosensing platform.
Wang C; Zhang Y; Tang W; Wang C; Han Y; Qiang L; Gao J; Liu H; Han L
Anal Chim Acta; 2021 Sep; 1178():338791. PubMed ID: 34482866
[TBL] [Abstract] [Full Text] [Related]
[Next]
